drugset / Trial / NCT02560298

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

NCT02560298 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same place as the primary tumor, or spread to other places in the body. Drugs used in chemotherapy, such as cisplatin, fluorouracil, carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin and fluorouracil are more effective than carboplatin and paclitaxel in treating anal cancer.

Timeline

Start
2016-08-23
Primary completion
2021-08-31
Completion
2023-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule — —
Subject Carboplatin Small molecule — Intravenous
Subject Cisplatin Other / unclassified — Intravenous
Subject Paclitaxel Small molecule — Intravenous
Subject fluorouracil Small molecule — Intravenous